NexImmune, Inc. (NEXI)
NexImmune, Inc. is a clinical stage biotechnology company, which engages in the development of novel approach to immunotherapy designed to employ the body's own T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. Its product candidates are NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM. The company was founded by Kenneth C. Carter, Jonathan Schneck, and Mathias Oelke on June 7, 2011 and is headquartered in Gaithersburg, MD.
Address
9119 GAITHER ROAD
GAITHERSBURG, MD 20878
Founded
2011
Number of Employees
6
Website
http://www.neximmune.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)